Abstracts Archive - Page 950 of 2425 - ACR Meeting Abstracts

Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: 2879 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang ¹, Yu-fei Hao ², Sheng-xiao Zhang², Quan-run Li ³, Jing-yuan Yang ³, Jia-qian Zhang ¹, Guang-ying Liu ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a…
Abstract Number: 2880 • 2019 ACR/ARP Annual Meeting
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos¹, Laura Coates ², Laure Gossec ³, Slawomir Jeka ⁴, Antonio Mera ⁵, Barbara Schulz ⁶, Michael Rissler ⁶, Ayan Das Gupta ⁷, Chiara Perella ⁶ and Effie Pournara ⁸, ¹Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²University of Oxford, Oxford, United Kingdom, ³Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁴University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁵Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited…
Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Philip Mease¹, Laure Gossec ², Laura Coates ³, Alice B. Gottlieb ⁴, Deepak Assudani ⁵, Barbara Ink ⁵, Jason Coarse ⁶, Oscar Irvin-Sellers ⁵ and Dafna Gladman ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, ⁵UCB Pharma, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁷Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
Abstract Number: 2882 • 2019 ACR/ARP Annual Meeting
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Vera Golder¹, Molla Huq ², Rangi Kandane-Rathnayake ³, Worawit Louthrenoo ⁴, Shue Fen Luo ⁵, Yeong-Jian Wu ⁵, Aisha Lateef ⁶, Sargunan Sockalingam ⁷, Sandra Navarra ⁸, Leonid Zamora ⁹, Laniyati Hamijoyo ¹⁰, Yasuhiro Katsumata ¹¹, Masayoshi Harigai ¹², Madelynn Chan ¹³, Sean O'Neill ¹⁴, Fiona Goldblatt ¹⁵, Chak Sing Lau ¹⁶, Zhanguo Li ¹⁷, Alberta Hoi ¹⁸, Mandana Nikpour ¹⁹ and Eric Morand ¹, ¹Monash University, Melbourne, Victoria, Australia, ²University of Melbourne, Melbourne, Australia, ³Monash University, Melbourne, Australia, ⁴Chiang Mai University Hospital, Chiang Mai, Thailand, ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas Hospital, Manila, Philippines, ⁹Santo Tomas Hospital, Manila, Philippines, ¹⁰Padjadjaran University, Bandung, Indonesia, ¹¹Tokyo Women's University, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴University of New South Wales, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁹St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) is a treatment endpoint for SLE that has been shown in prospective validation studies to be associated…
Abstract Number: 2883 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
April Barnado¹, Lee Wheless ¹, Leslie Crofford ² and Joshua Denny ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with > 100 known risk alleles. Some of these risk alleles associate with ACR SLE criteria…
Abstract Number: 2884 • 2019 ACR/ARP Annual Meeting
Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years
Mitra Moazzami¹, Vibeke Strand ², Jiandong Su ³ and Zahi Touma ⁴, ¹George Washington University, Washington, DC, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Fatigue is very common in SLE patients. We aim to: 1) determine if different trajectories of fatigue associate with specific latent classes of disease…
Abstract Number: 2885 • 2019 ACR/ARP Annual Meeting
An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
Chiara Bellocchi ¹, Álvaro Fernández-Ochoa ², Gaia Montanelli ³, Barbara Vigone ³, Alessandro Santaniello ³, Rosa Quirantes-Piné ⁴, Isabel Borrás-Linares ⁴, Maria Gerosa ⁵, Carolina Artusi ⁶, Roberta Gualtierotti ⁶, Antonio Segura-Carrettero ⁴, Marta E. Alarcón-Riquelme ⁷ and Lorenzo Beretta³, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, University of Milan, Milan, Italy, Milan, Italy, ². Department of Analytical Chemistry, University of Granada, Granada, Spain, Granda, Spain, ³Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, Milan, Italy, ⁴Department of Analytical Chemistry, University of Granada, Granada, Spain, Granada, Spain, ⁵Istituto Ortopedico Gaetano Pini, University of Milan, Milan, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, Milan, Italy, ⁷Centro de Genómica e Investigaciones Oncológicas Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain
Background/Purpose: Gut microbiota may be relevant in the regulation of immune processes and in the development of systemic autoimmune diseases (SADs). A reduction of microbiota…
Abstract Number: 2886 • 2019 ACR/ARP Annual Meeting
Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries
Emily Somers¹, Lu Wang ², W Joseph McCune ³, S Sam Lim ⁴, Cristina Drenkard ⁴, Elizabeth Ferucci ⁵, Maria Dall'Era ⁶, Caroline Gordon ⁷, Charles Helmick ⁸, Hilary Parton ⁹ and Peter Izmirly ¹⁰, ¹University of Michigan Schools of Medicine & Public Health, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴Emory University, Atlanta, GA, ⁵Alaska Native Tribal Health Consortium, Anchorage, AK, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁹New York City Department of Health & Mental Hygiene, Long Island City, NY, ¹⁰NYU School of Medicine, New York
Background/Purpose: The heterogeneity of the clinical manifestations of systemic lupus erythematosus (SLE) and lack of a diagnostic test make SLE difficult for epidemiologists to study.…
Abstract Number: 2887 • 2019 ACR/ARP Annual Meeting
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Sonali Narain¹, Daniel Wallace ², Chaim Putterman ³, Cristina Arriens ⁴, Anca Askanase ⁵, Kenneth Kalunian ⁶, Christopher Collins ⁷, Amit Saxena ⁸, Elena Massarotti ⁹, Roberta Alexander ¹⁰, Claudia Ibarra ¹⁰, Tyler O'Malley ¹¹, John Conklin ¹⁰, Rosalind Ramsey-Goldman ¹², Joseph Ahearn ¹³, Susan Manzi ¹³, Arthur Weinstein ¹⁰ and Thierry Dervieux ¹⁰, ¹Northwell Health, Great Neck, Long Island, NY, ²Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ³Albert Einstein College of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Columbia University, New York, ⁶Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁷MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁸New York University School of Medicine, New York, NY, ⁹Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ¹⁰Exagen, Vista, CA, ¹¹Exagen, Oceanside, CA, ¹²Northwestern University, Chicago, IL, ¹³Allegheny Health Network, Pittsburgh
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are stable forms of classical complement activation ex-vivo, with high sensitivity and specificity for systemic lupus erythematosus (SLE). We…
Abstract Number: 2888 • 2019 ACR/ARP Annual Meeting
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
Francine Castillo¹, Adrienne Strait ², Michael Evans ³, Julia Kay ⁴, Milena Gianfrancesco ⁵, Zara Izadi ⁶, Laura Trupin ¹, Mylien Hoang ⁷, James Shalaby ⁸, Gabriela Schmajuk ⁹ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, CA, ²UCSF School of Medicine, San Francisco, CA, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, ⁶UCSF Division of Rheumatology, San Francisco, ⁷Touro University, San Francisco, ⁸Elimu Informatics, San Francisco, ⁹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Prednisone is commonly used to treat rheumatic diseases, yet few comparative effectiveness studies on different dosing regimens are available. Electronic health records (EHR) and…
Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Natalie McCormick¹, Zachary Wallace ², Chio Yokose ³, April Jorge ³, Chana Sacks ⁴, John Hsu ⁵ and Hyon K. Choi ³, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁵Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…
Abstract Number: 2890 • 2019 ACR/ARP Annual Meeting
The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Mark Tatangelo¹, George Tomlinson ², Edward Keystone ³, Michael Paterson ⁴, Nick Bansback ⁵ and Claire Bombardier ⁶, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Institute for Clinical Evaluative Sciences, Toronto, Canada, ⁵University of British Columbia, Vancouver, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The direct and indirect effects of rheumatoid arthritis (RA) are difficult to measure in observational studies because: (1) The inflammatory effects of RA are…
Abstract Number: 2891 • 2019 ACR/ARP Annual Meeting
Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
James Sullivan¹, Jeffrey Katz ² and Elena Losina ³, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital/Harvard Medical School, Boston, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Knee OA is a disabling condition affecting over 14 million adults in the US. NSAIDs provide only short-term pain relief, creating the need for…
Abstract Number: 2892 • 2019 ACR/ARP Annual Meeting
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Celine van de Laar¹, Martijn A.H. Oude Voshaar ², Carly Janssen ³, Matthijs Janssen ⁴, Maiwenn Al ⁵ and Mart A.F.J. van de Laar ⁶, ¹Transparency in Healthcare B.V., Hengelo, Overijssel, Netherlands, ²Transparency in Healthcare B.V. and Department of Psychology, Health & Technology, University of Twente, Hengelo, Netherlands, ³Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁴Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands, ⁵Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].